

## The Effect of Oral Progesterone on Deceasing Preterm Labor in Patients with a History of Preterm Labor

Shohreh Alimohammadi<sup>1</sup>, Maryam Jamali<sup>2</sup>, \*Ziba Mohsenpour<sup>3</sup>, Fatemeh Mohsenpour<sup>4</sup>,  
Seyed Mahdi Nedadahandeh<sup>5</sup>, Mazyar Jamali<sup>6</sup>

<sup>1</sup>Perinathologist, Hamadan University of Medical Sciences, Hamadan, Iran. <sup>2</sup>Obstetrician and Gynecologist, Hamadan University of Medical Sciences, Hamadan, Iran. <sup>3</sup>Kowsar Hospital, Shiraz University of Medical Sciences, Shiraz, Iran. <sup>4</sup>Obstetrician and Gynecologist, Hamadan University of Medical Sciences, Hamadan, Iran. <sup>5</sup>Anesthesiologist, Hamadan University of Medical Sciences, Hamadan, Iran. <sup>6</sup>General Surgery Resident, Khorramabad University of Medical Sciences, Khorramabad, Iran.

### Abstract

#### Background

Preterm birth with a prevalence of about 10% causes 75-95% of prenatal mortality, and one of the effective factors of it is hormonal factors. This study aimed to investigate the effect of oral medroxy progesterone on reducing preterm labor in women with a history of preterm labor.

#### Materials and Methods

This double-blinded clinical trial was performed on 214 pregnant women with the history of at least one preterm labor referred to midwifery clinic of Fatemeh Hospital, Shiraz, Iran, during 2017 to 2018. One hundred and seven women underwent treatment with oral medroxy progesterone (100 mg per day), and 107 individuals were prescribed placebo, and prenatal care was performed routinely. Recent pregnancy course and delivery time were compared in two groups. Data were analyzed by SPSS software version 16.0.

#### Results

Gestational age with a mean of  $30 \pm 3.89$  and  $36 \pm 2.11$  weeks, respectively in control and intervention groups differed significantly ( $P < 0.05$ ). The number of referrals to hospital due to preterm labor, the age of patients at first referral due to preterm labor, and age of delivery in both groups of receiving progesterone and placebo were significantly different ( $P < 0.05$ ).

#### Conclusion

Based on the results of the current study using 100 mg oral progesterone per day in weeks 16-36 of pregnancy was effective in reduction of preterm labor, and caused improved gestational age in mothers.

**Key Words:** Oral Medroxy Progesterone, Pregnant women, Preterm Labor.

\*Please cite this article as: Alimohammadi Sh, Jamali M, Mohsenpour Z, Mohsenpour F, Nedadahandeh SM, Jamali M. The Effect of Oral Progesterone on Deceasing Preterm Labor in Patients with a History of Preterm Labor. *Int J Pediatr* 2020; 8(1): 107115-7172. DOI: **10.22038/ijp.2019.44345.3673**

#### \*Corresponding Author:

Ziba Mohsenpour, (M.D), Kowsar Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.

Email: ziba.mohsenpour@gmail.com

Received date: Sept.20, 2019; Accepted date: Dec.12, 2019

## 1- INTRODUCTION

Preterm labor is referred to birth before 37<sup>th</sup> week of pregnancy, its prevalence in developed countries varies between 6-12%, and in developing countries this prevalence is 22-26%, and is also one of the reasons for prenatal mortality (1-5). The chance for survival of premature fetuses increases with increasing gestational age. In addition to mortality, premature infant is susceptible to physical and intelligence disorders, and the cost of caring for these infants in intensive care units is high (6-9). Etiology of preterm labor is unclear but risk factors related to maternal aspects, infections, mothers' life-style, chronic diseases in mother, hereditary factors, and hormonal factors are known; one of the important risk factors is history of previous preterm labor as the risk of later preterm labor will be increased by each time of previous preterm labor (10).

Despite many progresses in treatment of preterm labor, its prevalence has not been decreased in the last decades (11). Progesterone, one of the hormones secreted by the placenta, is essential for maintaining pregnancy survival. Weekly injection of 17-alpha hydroxyprogesterone caproate or using daily progesterone suppository causes decrease in the number of preterm labors in high-risk women with the history of preterm labors (12-14). Various clinical trials investigated the effect of 17-hydroxyprogesterone and vaginal progesterone in patients with history of preterm labor (15-17).

On the other hand O'Brien et al., found that using progesterone gel is not effective in reducing preterm labor in comparison to placebo (18). Several studies showed that using progesterone prevents preterm labor (12-17). The medication commonly used in the studies was 17-hydroxyprogesterone. Using 17-hydroxyprogesterone has shown promising results but intramuscular injection is

painful and requires somebody to help inject it. Micronized progesterone has been used orally and vaginally in defects of luteal phase and loss of early stages of pregnancy. However, vaginal route is not acceptable by most of the patients, since it causes increase in vaginal secretions that bothers the patient. Therefore, since the oral progesterone to prevent preterm labor has not been investigated, the aim of the current study is to investigate efficacy, safety and the effects of oral progesterone (Medroxyprogesterone) to prevent preterm labor in mothers with history of preterm labor.

## 2- MATERIALS AND METHODS

### 2-1. Study design and population

This study was a clinical trial performed on pregnant women aged 18-35 years with history of preterm labor referred to midwifery clinic of Fatemeh Hospital, Shiraz, Iran (covered by Shiraz University of Medical Sciences) in the second half of year 2018 and first half of year 2019. Two hundred and fourteen pregnant women were selected randomly, all of which had history of preterm labor. Then the participants were allocated in two equal groups (107 patients in case group and 107 patients in control group). Both groups were matched based on age of mother, partum, and history of preterm labor. For all of the patients a questionnaire consisted of age, gravity, abortion history, preterm labor history, the underlying reason for preterm labor, the type of previous labor (vaginal or cesarean section) and the weight of previous child was filled.

### 2-2. Inclusion criteria

Inclusion criteria were pregnant women aged 18-35 years with a history of spontaneous preterm labor between weeks 20-36 of gestation which had no contraindication for continuing their pregnancy.

### 2-3. Exclusion criteria

Exclusion criteria were women with fetal anomaly, vaginal bleeding during first semester of pregnancy, active hepatic disease, and the age lower than 18 years or more than 35 years.

#### 2-4. Ethical consideration

After approval by ethical committee of Hamedan University (IR.UMSHA.REC.1395.377), firstly the protocol of the study was completely explained to the participants, and in case of agreement of mothers, they were entered to the study. Participating in the study and also exit from the study was voluntary. This study is registered at clinical trial site with the code of IRCT201710079014N192.

#### 2-5. Intervention

After random allocation of mothers in two groups of intervention (mothers with a history of preterm labor treated by medroxyprogesterone), and control (placebo group), midwifery examination and systematical and physical were performed by gynecologist in first visit for both intervention and control groups. Gestational age was calculated based on last menstrual period (LMP), and crown-rump length before week 12, and also Biparietal diameter (BPD) diameter in second trimester was considered. Examination by speculum was done at first visit. Transabdominal sonography (TAS) between weeks 16-18 for serial biometry of fetus, placental location, fluid volume, and rejection of fetal anomalies were performed. TVS during first and second weeks was performed to measure cervix length and diameter of internal os, which cerclage is required for assessment. Patients in control group were prescribed placebo capsule (manufactured by Shiraz school of pharmacy and contained gelatin) twice daily and patients in intervention group were prescribed 100mg medroxyprogesterone (manufactured by Aboureihan Pharmaceutical Company,

Iran) twice daily from week 16 of gestation to a maximum of 36<sup>th</sup> week of gestation. This regimen was continued until 36<sup>th</sup> week or until the time of labor (each happened sooner). Women were asked to refer for check-up every two weeks. Patients and physician were not aware of the dose and type of the prescribed medication until time of labor and end of the intervention. In the intervention group patients with preterm labor were treated based on protocol, and the study results were assessed based on gestational age, and classification was as follows: below 28 weeks, 28<sup>th</sup> to 32<sup>nd</sup> week, 32<sup>nd</sup> to 34<sup>th</sup> week, 34<sup>th</sup> to 36<sup>th</sup> week, and over 36<sup>th</sup> week. For control group routine prenatal care was performed.

#### 2-6. Data Analyses

Then pregnancy results in both groups were compared. Obtained results for both groups were analyzed by SPSS software (version 16.0). Frequency tables to describe data and Chi-square test and T-test to compare between case and control groups were used. P-value less than 0.05 were considered as significant. Normality of distribution was assessed by Kolmogorov-Smirnov

### 3- RESULTS

Two hundred and fourteen individuals participated in this study, of which 107 individuals were in control group and 107 individuals were in intervention group. There were no significant differences for age, educational level, and social class between two study groups ( $P > 0.05$ ). The total times of referral to hospital in two groups with a mean of  $2.89 \pm 1.04$  times for control group and  $2.61 \pm 1.42$  times for intervention group did not differ significantly ( $P < 0.05$ ). The first referral of mothers to hospital in the control group was at 26<sup>th</sup> week of gestation and in the intervention group was 29<sup>th</sup> week ( $P < 0.05$ ).

The number of referrals to hospital due to preterm labor was  $0.59 \pm 1.38$  times in control group and  $0.44 \pm 1.23$  times in intervention group ( $P < 0.05$ ). The total lost pregnancies, patient's age, and the number of gravidities were not significantly different ( $P > 0.05$ ). Gestational age was about  $30 \pm 3.89$  weeks in control group and  $36 \pm 2.11$  weeks in intervention group and this difference was significant between groups ( $P < 0.05$ ). There were no significant differences in regard to other outcomes of pregnancy such as infant death, infant infection, fetal death and number of abortions between groups receiving progesterone and placebo ( $P > 0.05$ ). The number of abortions in first trimester were not significantly different but the number of abortions in second trimester with a mean of  $0.45 \pm 1.17$  in control group and  $0.19 \pm 1.67$  in intervention group was significantly different.

The results showed that 4% (5 individuals) in control group experienced labor after 36<sup>th</sup> week and about 50% (50 individuals) in intervention group experienced labor after 36<sup>th</sup> labor. Twenty-seven individuals (25%) in control group delivered before 28<sup>th</sup> week of gestation, and none of the individuals in intervention group delivered before 28<sup>th</sup> week of gestation. Twenty individuals (18.7%) in control group and 1.9% (2 individuals) in intervention group delivered between 28<sup>th</sup>-32<sup>nd</sup> week of gestation. Forty-six individuals (43%) in control group and 11 individuals (10.3%) in intervention group delivered during weeks 32-34, and 9 individuals (8.4%) vs. 44 individuals (41%) in intervention group delivered between 34<sup>th</sup>-36<sup>th</sup> week of gestation.

#### 4- DISCUSSION

The current study aimed to assess efficacy, safety, and the effects of oral progesterone for prevention of preterm labor in mothers with a history of preterm labor. Despite numerous clinical trials on

preterm labor and many advances in midwifery science, the best therapeutic method is yet challenging. Unfortunately, in the last two decades no progress has been made in reducing preterm labor (19, 20). In the current study consumption of 100mg/day of progesterone from 16<sup>th</sup> week of gestation showed increased gestational age in group receiving progesterone in comparison to control group ( $P < 0.05$ ). A review study in 2006 reported that initiation of prescription of progesterone from second trimester might reduce the risk of preterm labor before 37<sup>th</sup> week of gestation (21). In the study by Bahadori et al., mean and standard deviation of gestational age at the labor time in the progesterone group and control group differed significantly (22). Spong et al., in their study in 2005 in America on women with preterm labor found that mean gestational age at labor time in intervention group with progesterone was significantly higher than control group (6).

Other studies also reported the effect of progesterone on reducing preterm labor (10, 15, 19, 23-26). In addition, some previous studies showed the lack of effectiveness of progesterone in reducing risk of preterm labor (27, 28). Senat et al., in a study in 2013 in France found that treatment with injectable progesterone causes significant change in the rate of preterm labor (29). In the study by Grobman et al., in 2012 in America, the rate of preterm labor was not significantly different between groups receiving progesterone and placebo (30). Salari performed a study in 2012 in Iran on 100 pregnant women with the symptoms of preterm labor, but he did not observe any significant difference between two groups receiving progesterone and isoxsuprine for the rate of preterm labor (31). Although mechanism of the effect of progesterone in prolongation of pregnancy is not yet understood, but according to studies performed up to date in this context,

progesterone relaxes myometrial smooth muscles, inhibits oxytocin, and inhibits formation of connections between myometrial cells of uterus which is essential for coordination of uterus muscles which results in labor (32). However, this point should be considered that prescribed progesterone doses in various studies were different. For example, Saghafi et al., used 250 progesterone vial weekly, intramuscular (19), and the progesterone dose of our study was 100mg per day. It seems that minimum prescribed progesterone is also effective in reducing preterm labor, and there is no need to prescribe higher doses of progesterone. On the other hand, oral progesterone was not used in any of the previous investigations. In this study for other outcomes of pregnancy such as neonatal death, neonatal infection, fetal death, and the number of abortions in two groups receiving progesterone and placebo, no significant difference was observed which is consistent with Briery et al.'s study (33). In the current study, frequency of labor before 32nd week in women treated by oral medroxyprogesterone in comparison to control group was significantly lower. Despite numerous studies in the context of the effect of progesterone for prevention of preterm labor, the effect of progesterone on mortality and complications before birth is controversial and further studies in this context are needed (34-36).

## 5- CONCLUSION

Based on the results of the current study using oral progesterone (100 mg per day from 16<sup>th</sup> week until 36<sup>th</sup> week of gestation) is effective in the rate of preterm labor and improves gestational age. Performing studies with larger sample size in order for better investigation of the role of oral progesterone in prevention of preterm labor are recommended. Since some factors such as high rate of previous lost pregnancies represents underlying

problem of the patient, and there is no significant association for control and intervention group in this context. Therefore, it seems that correct selection of individuals who may take advantage of treatment with progesterone in order to prevent preterm labor is cost effective and causes reduction in unnecessary costs.

## 6- ACKNOWLEDGMENT

Finally, I thank all the professors, especially Dr. Ali Mohammadi, who assisted in this research.

**7- CONFLICT OF INTEREST:** None.

## 8- REFERENCES

1. Gonzalez R. Parenteral Administration of Progesterone for Preventing Preterm Birth: RHL commentary. The WHO Reproductive Health Library; Geneva: World Health Organization; 2008.
2. Cunningham FG, Leveno KG, Bloom SL, Has JC, Gillstrap LC, Wenstrom KD. Williams obstetrics. 22nd ed. New York: McGrawHill; 2005.
3. Kramer MS, Demissie K, Yang H, Platt RW, Sauve R, Liston R. The contribution of mild and moderate preterm birth to infant mortality. Fetal and Infant Health Study Group of the Canadian Perinatal Surveillance System. *JAMA* 2000 16; 284(7):8439.
4. Wood NS, Marlow N, Costeloe K, Gibson AT, Wilkinson AR. Neurologic and developmental disability after extremely preterm birth. EPICure Study Group. *N Engl J Med* 2000; 343(6):378–84.
5. Delavari AR, Mahdavihazaveh AR, Norozinegad A, Yarahmadi Sh. National program for prevention and control of type 2 diabetes diseases. 2th ed. Iran: Seda publishers; 2004. pp.14-36.
6. Spong CY, Meis PJ, Thom EA, Sibai B, Dombrowski MP, Moawad AH, et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. *Am J Obstet Gynecol* 2005; 193(3 Pt 2):1127–31.

7. Gilbert WM, Nesbitt TS, Danielsen B. The cost of prematurity: quantification by gestational age and birth weight. *Obstet Gynecol* 2003; 102(3):488–92.
8. Petrou S, Mehta Z, Hockley C, CookMozaffari P, Henderson J, Goldacre M. The impact of preterm birth on hospital admissions and costs during the first 5 years of life. *Pediatrics* 2003; 112 (6 Pt 1):1290–97.
9. Hoyert DL, Mathews TJ, Menacker F, Strobino DM, Guyer B. Annual Summary of Vital Statistics: 2004. *Pediatrics*. 2006; 117: 168–83.
10. Odibo AO, Stamilio DM, Macones GA, Polsky D. 17 $\alpha$ hydroxyprogesterone caproate for the prevention of preterm delivery: A costeffectiveness analysis. *Obstet Gynecol* 2006; 108(3 Pt 1):4929.
11. Guvenal T, Kantas E, Erselcan T, Culhaoglu Y, Cetin A. Beta human chorionic gonadotropin and prolactin assays in cervicovaginal secretions as a predictor of preterm delivery. *Int J Gynecol Obstet*.2001; 75(3):229-34.
12. Peltier MR, Tee SC, Smulian JC. Effect of progesterone on proinflammatory cytokine production by monocytes stimulated with pathogens associated with preterm birth. *Am J Reprod Immunol* 2008; 60(4): 346-53.
13. Norman JE, Shennan A, Bennett P, Thornton S, Robson S, et al. Trial protocol OPPTIMUM- does progesterone prophylaxis for the prevention of preterm labour improve outcome? *BMC Pregnancy Childbirth* 2012; 6(12): 79.
14. Mizrahi M, Furman B, shoham –Vardi I, vardi H, Maymon E, Mazor M. perinatal outcome and peripartum complications in preterm singleton and twins deliveries: a comparative study. *Eur J Obstet Gynecol reprod Biol*, 1999; 87 (1): 55-61.
15. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. *Am J Obstet Gynecol* 2003; 188(2): 419-24.
16. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent preterm delivery by 17 $\alpha$ -hydroxyprogesterone caproate. *N Engl J Med* 2003; 348(24): 2379-85.
17. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH. Progesterone and the risk of preterm birth among women with a short cervix. *N Engl J Med* 2007; 357(5): 462-9.
18. O'Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. *Ultrasound Obstet Gynecol* 2007; 30(5): 687-96.
19. Saghafi N , Khadem N, Mohajeri T, Shakeri M, Amini M. Efficacy of 17 $\alpha$ -Hydroxyprogesterone Caproate in Preterm Delivery Prevention. *The Iranian Journal of Obstetrics, Gynecology and Infertility*. 2011; 14(2): 28-33.
20. Martin JA, Hamilton BE, Ventura SJ, Menacker F, Park MM. Births: final data for 2000. *Natl Vital Stat Rep*. 2002; 50(5):1-101.
21. Mackenzie R, Walker M, Armson A, Hannah ME. Progesterone for the prevention of preterm birth among women at increased risk: a systematic review and meta-analysis of randomized controlled trials. *Am J Obstet Gynecol*. 2006; 194(5):1234-42.
22. Bahadori F, Borna S, Shakouie nejad S, Sahabi N. Progesterone and the latency period: threatened preterm labor. *Tehran Univ Med J*. 2008; 66 (3):208-213
23. Papiernik, Double blind study of an agent to prevent preterm delivery among women at increased risk Edition Schering 1970; 4(3):65-68.
24. Johnson JW, Austin KL, Jones GS, Davis DH, King TM. Efficacy of 17 $\alpha$ hydroxyprogesterone caproate in the prevention of premature labor. *N Engl J Med* 1975; 293(4):675–80.
25. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH; Fetal Medicine Foundation

Second Trimester Screening. Progesterone and the risk of preterm birth among women with a short cervix. *N Engl J Med* 2007; 357(5):4629.

26. Petrini JR, Callaghan WM, Klebanoff M, Green NS, Lackritz EM, Howse JL, et al. Estimated effect of 17 alphahydroxyprogesterone caproate on preterm birth in the United States. *Obstet Gynecol* 2005; 105(2):26772.

27. Goldstein P, Berrier J, Rosen S, Sacks HS, Chalmers TC. A meta-analysis of randomized control trials of progestational agents in pregnancy. *Br J Obstet Gynecol* 1989; 96(3):265-74.

28. Hartikainen-Sorri AL, Kauppila A, Tuimala R. Inefficacy of 17 alpha-hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. *Obstet Gynecol.* 1980; 56(6):692-5.

29. Senat MV, Porcher R, Winer N, Vayssière C, Deruelle P, Capelle M, et al. Prevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. *Am J Obstet Gynecol.* 2013; 208(3):194.e1-8.

30. Grobman WA, Thom EA, Spong CY, Iams JD, Saade GR, Mercer BM, et al. 17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. *Am J Obstet Gynecol.* 2012 Nov;207(5):390.e1-8.

31. Salari Z, Mirzaei S, Ravari A, Mirzaei T. The Comparison between Vaginal Progesterone

and Isoxuprine Tab on Duration of Latent Phase after Controlled Preterm Labor. *JRUMS.* 2012; 11 (4):301-12.

32. March of Dimes Foundation. Effectiveness of progesterone in reducing preterm birth may be altered by genetic predisposition. *Science daily* [Access time 2009 Feb.7]: Available at:

<http://www.sciencedaily.com/releases/2009/01/090130084153.htm>.

33. Briery CM, Veillon EW, Klauser CK, Martin RW, Magann EF, Chauhan SP, et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. *Am J Obstet Gynecol* 2011; 204(1): 54-5.

34. Lotfalizadeh M, Ghomian N, Reyhani A. The effects of progesterone therapy on the gestation length and reduction of neonatal complications in patients who had received tocolytic therapy for acute phase of preterm labor. *Iran Red Crescent Med J* 2013; 15(10): e7947.

35. Ngai I, Marji M, Neto N, Garretto D, Sheen JJ, Garry DJ. The effectiveness of 17alphahydroxyprogesterone caproate in obese women for prevention of preterm delivery. *Obstet Gynecol* 2014; 123(Suppl 1): 161S-2S.

36. Ngai I, Sheen JJ, Garretto D, Govindappagari S, Bernstein P, Garry DJ. Progesterone (17alpha-hydroxyprogesterone caproate) for prevention of preterm birth and preeclampsia. *Obstet Gynecol* 2014; 123 (Suppl.1):162S.